摘要
目的观察与分析大麻素受体2(CB2)在尖锐湿疣和子宫颈癌中的表达及意义。方法采集尖锐湿疣、宫颈上皮内瘤变及子宫颈癌患者标本,以免疫组织化学法及实时定量聚合酶链反应(RT-PCR)法检测CB2在组织中的表达情况。结果免疫组织化学法检测显示,CB2在尖锐湿疣、子宫颈上皮内瘤变、子宫颈癌组织中均有表达;累积光密度值分析显示,CB2在尖锐湿疣全子宫切除术后阴道残端出血组织中表达量最低(25 361.33±15 462.71),在子宫颈癌组织中表达量最高(69 863.66±14 203.88),子宫颈上皮内瘤变组织中则居中,但随子宫颈上皮内瘤变分级程度不断增高而表达量增加,子宫颈上皮内瘤变低分级为63 571.98±13 417.21,高分级为65 719.27±13 651.09,差异有统计学意义(P<0.05);CB2 mRNA在尖锐湿疣组织中表达量最低,与内参β-actin mRNA比值为1.35±0.31,在子宫颈癌组织中表达量最高,与β-actin mRNA比值为7.49±0.98,子宫颈上皮内瘤变组织中表达居中,呈现随子宫颈上皮内瘤变分级程度增高而增加的趋势,其在低分级组织中为3.54±0.42,高分级组织中为5.56±0.38,差异均具有统计学意义(P<0.05)。结论 CB2可能参与了子宫颈癌的发生发展过程。
Objective To observe and analyze the expression of cannabinoid receptor 2(CB2) in condyloma acuminatum(CA) and cervical carcinoma(CC) and explore the significance.Methods Real time-polymerase chain reaction(RT-PCR) and immunohistochemistry were applied to detect CB2 expression in CA,CC and cervical intraepithelial neoplasia(CIN)tissues.Results The expression of CB2 could be found in CA,CC and CIN tissues through immunohistochemical method.Integrated option density(IOD) analysis of immunohistochemistry showed a significant increase of CB2 expression in CC tissue(69 863.66±14 203.88) than those in CA tissue(25 361.33±15 462.71) and CIN tissue,and CB2 expression in higher CIN classification(65 719.27±13 651.09) increased significantly than that in lower CIN classification(63 571.98±13 417.21)(P0.05).The same trend was found by RT-PCR tests,the level(the ratio with β-actin) of CB2 mRNA expression was lowest in CA tissue(1.35±0.31) and highest in CC tissue(7.49±0.98),mediately in CIN tissue.With the upgrade of CIN classification,the expression of CB2 mRNA in CIN tissue increased,which was 5.56±0.38 in higher CIN classification tissue and 3.54±0.42 in lower CIN classification tissue,the differences were significant(P0.05).Conclusion CB2 receptor probably plays a role in occurrence and development of CC.
出处
《新乡医学院学报》
CAS
2012年第12期911-913,共3页
Journal of Xinxiang Medical University
基金
深圳市宝安区科技计划项目(编号:2009494)
关键词
大麻素受体2
尖锐湿疣
子宫颈癌
cannabinoid receptor 2
condyloma acuminatum
cervical carcinoma